<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7240">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05066997</url>
  </required_header>
  <id_info>
    <org_study_id>DX219</org_study_id>
    <nct_id>NCT05066997</nct_id>
  </id_info>
  <brief_title>Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Diabetic Macular Edema</brief_title>
  <official_title>A Pivotal, Double-Masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oculis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oculis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of OCS-01 ophthalmic&#xD;
      suspension versus vehicle alone in subjects with DME&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a Phase 3 Pivotal, Double-Masked, Randomized, 2-stage, Multicenter Study of the&#xD;
      Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema.&#xD;
&#xD;
      Stage 1 will confirm the safety and efficacy of OCS-01 versus Vehicle alone in subjects with&#xD;
      diabetic macular edema (DME).&#xD;
&#xD;
      Stage 2 will evaluate the efficacy and safety of OCS-01 in subjects with DME.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in BCVA ETDRS letters (Best Corrected Visual Acuity Early Treatment Diabetic Retinopathy Score</measure>
    <time_frame>Week 52</time_frame>
    <description>Stage 1:&#xD;
Mean change in BCVA ETDRS letters score compared with baseline. ≤ 65 and ≥ 24: A numerical increase indicates improvement&#xD;
Stage 2:&#xD;
Mean change in BCVA ETDRS letters score at Visit 9 (Week 52) compared with baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety measures</measure>
    <time_frame>at each visit throughout the study up to week 52</time_frame>
    <description>• Incidence in Treatment Emergent Adverse Events assessed by site</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">482</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Active treatment arm: OCS-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Stage 1: Active treatment arm: OCS-01 - dosing regimen 1 for 6 weeks followed by dosing regimen 2 for 6 weeks.&#xD;
. In Stage 2, subjects will receive the dosing regimen from Stage 1 for OCS-01 for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In stage 1: Vehicle: dosing regimen 1 for 6 weeks followed by dosing regimen 2 for 6 weeks.&#xD;
In Stage 2, subjects will receive the matched dosing regimen for Vehicle for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active treatment arm: OCS-01 (dexamethasone)</intervention_name>
    <description>The interventional drug OCS-01 eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit</description>
    <arm_group_label>Active treatment arm: OCS-01</arm_group_label>
    <other_name>Dexamethasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>The vehicle drug (placebo) eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit</description>
    <arm_group_label>Vehicle placebo arm</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          1. Have a signed informed consent form before any study-specific procedures are&#xD;
             performed;&#xD;
&#xD;
          2. Have DME with presence of intraretinal and/or subretinal fluid in the study eye, with&#xD;
             central subfield thickness (CST) of ≥310 µm (may be adjusted based on gender specific&#xD;
             requirements) by SD-OCT at screening (Visit 1) (as assessed by an independent reading&#xD;
             center); CST is not part of the eligibility reconfirmation on Day 1&#xD;
&#xD;
          3. Have a documented diagnosis of type 1 or type 2 diabetes mellitus and a glycosylated&#xD;
             hemoglobin A1c (HbA1c) of ≤ 12.0% (≤108 mmol/mol) at Visit 1 (Screening).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        1) Have macular edema considered to be because of a cause other than DME.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oculis Investigative Site</last_name>
    <role>Principal Investigator</role>
    <affiliation>Winter Haven, FL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oculis Investigative Site</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eugene, OR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oculis Investigative Site</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beverly Hills, CA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oculis Investigative Site</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hagerstown, MD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naleni Eigensatz</last_name>
    <phone>+41 21 711 3970</phone>
    <email>naleni.eigensatz@oculis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oculis Investigative Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

